Delivery Order SPE2DB24D3013-SPE2DB25FFLXZ

Award Date 5/21/25
Potential Completion Date 5/22/25
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,757.10, is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product. The contract is a firm fixed price delivery order, with a period of performance through May 12, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product, with a ceiling value of $3,118.90 and a performance period ending on May 15, 2025. The contract is a Firm Fixed Price, non-set-aside award. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,678.35, is for the delivery of 4,567,859,053 units of the medication XELJANZ XR 11 MG TABLET. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $35,395.89, is for the delivery of XELJANZ XR 11 MG TABLET UU 30S and has an ultimate completion date of April 1, 2025. The contract is a firm-fixed-price type and was not set aside for any specific business category. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,213.10, is for the supply of XELJANZ XR 11MG TB 30S, a prescription medication. The contract is a firm fixed-price delivery order, with a period of performance through June 6, 2025. This contract is not designated as a set-aside. AmerisourceBergen Drug Corporation holds a large...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,618.23, is for the delivery of XELJANZ XR 11 MG TABLET 30S to support federal healthcare programs. The contract is a firm fixed-price, delivery order type, with a period of performance through December 12, 2024. This award is not designated as a set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,758.13 fixed-price delivery order is for the supply of XELJANZ XR 11 MG TABLET UU 30S, a specialty medication. The contract has an ultimate completion date of January 17, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $33,115.77, is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product. The contract is a firm fixed-price delivery order, with a completion date of May 15, 2024. The contract was not set aside for any specific business type. Amerisourcebergen Drug Corp is a for-profit...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET with a ceiling value of $74,732.48. The order is a firm fixed-price contract and is not set aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth $999,999,999.00, which provides a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET UU 30S. The contract has a firm-fixed price and a ceiling value of $7,586.53. It is not set aside and runs through May 19, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999.00. This IDC provides a comprehensive...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFLXZ
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,370.62 firm fixed price contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, with a performance period through May 22, 2025. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle through December 2026. This allows the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The contract award is not designated as a set-aside.

Generated 8/20/25, 9:53 AM